114 related articles for article (PubMed ID: 16328413)
1. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Gan HK; Mitchell PL; Galettis P; Davis ID; Cebon J; de Souza P; Links M
Cancer Chemother Pharmacol; 2006 Aug; 58(2):157-64. PubMed ID: 16328413
[TBL] [Abstract][Full Text] [Related]
2. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
3. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Saridaki Z; Pappas P; Souglakos J; Nikolaidou M; Vardakis N; Kotsakis A; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):121-8. PubMed ID: 19415279
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Goel S; Bulgaru A; Hochster H; Wadler S; Zamboni W; Egorin M; Ivy P; Leibes L; Muggia F; Lockwood G; Harvey E; Renshaw G; Mani S
Ann Oncol; 2003 Nov; 14(11):1682-7. PubMed ID: 14581279
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
Mavroudis D; Kourousis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Samonis G; Georgoulias V
Semin Oncol; 2000 Feb; 27(1 Suppl 2):25-30. PubMed ID: 10697033
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
[TBL] [Abstract][Full Text] [Related]
8. Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Fizazi K; Ducreux M; Ruffié P; Bonnay M; Daniel C; Soria JC; Hill C; Fandi A; Poterre M; Smith M; Armand JP
J Clin Oncol; 2000 Jun; 18(11):2293-300. PubMed ID: 10829050
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Shibata S; Chow W; Frankel P; Juhasz A; Leong L; Lim D; Margolin K; Morgan R; Newman E; Somlo G; Yen Y; Synold T; Gandara D; Lenz HJ; Doroshow J
Cancer Chemother Pharmacol; 2007 Mar; 59(4):549-57. PubMed ID: 17051371
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors.
Misset JL; Gamelin E; Campone M; Delaloge S; Latz JE; Bozec L; Fumoleau P
Ann Oncol; 2004 Jul; 15(7):1123-9. PubMed ID: 15205208
[TBL] [Abstract][Full Text] [Related]
14. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Starling N; Hawkes EA; Chau I; Watkins D; Thomas J; Webb J; Brown G; Thomas K; Barbachano Y; Oates J; Cunningham D
Ann Oncol; 2012 Apr; 23(4):942-7. PubMed ID: 21750117
[TBL] [Abstract][Full Text] [Related]
15. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Tan BR; Brenner WS; Picus J; Marsh S; Gao F; Fournier C; Fracasso PM; James J; Yen-Revollo JL; McLeod HL
Ann Oncol; 2008 Oct; 19(10):1742-8. PubMed ID: 18534963
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.
Alberts SR; Townley PM; Goldberg RM; Cha SS; Moore DF; Krook JE; Pitot HC; Fitch TR; Wiesenfeld M; Mailliard JA; Sargent DJ
Ann Oncol; 2002 Apr; 13(4):553-7. PubMed ID: 12056705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
